The Volpara Health Technologies Ltd (ASX: VHT) share price is on course to finish the week with a strong gain.
On Friday afternoon the medical technology company’s shares are up almost 5.5% to $1.69.
Why is the Volpara share price charging higher?
Investors appear to have been scrambling to pick up the company’s shares today after it announced the completion of its US$14.59 million (~A$21.15 million) acquisition of MRS Systems.
MRS Systems is a medical software company that provides comprehensive patient tracking and communication, and a radiology reporting platform for sub-specialty radiology applications including breast and lung imaging.
It is a leading provider of breast clinic management software, with an estimated ~20% market share of breast clinics in the United States.
In the 2019 calendar year the company has forecast annual recurring revenue (ARR) of ~US$4.5 million. Including capital sales, MRS Systems expects ~US$7.5 million of total revenue over the 12 months.
Volpara made the acquisition as it provides it with an expanded and mature presence in the United States, an enlarged sales footprint and technical support, and product suites that are highly complementary. The latter is expected to provide both businesses with cross-selling opportunities.
In addition to this, management believes the combination of MRS clinical data and Volpara images will enrich Volpara’s AI capability.
Volpara’s CEO, Dr Ralph Highnam, said: “We are delighted to welcome MRS Systems and its people into the Volpara group. And we are excited about the opportunity to work alongside MRS Systems in the United States and to grow Volpara’s service offering in the increased number of US breast clinics to which Volpara now has immediate access. The acquisition has involved a tremendous effort from people in both organisations, and I would like to express my thanks to everyone as we look forward to the future with a stronger US base and an extended range of integrated products which will help detect breast cancer earlier.”
Volpara isn’t the only medical technology company on the rise today. The shares of both Nanosonics Ltd (ASX: NAN) and Pro Medicus Limited (ASX: PME) are outperforming the market by some distance on Friday.
Forget what just happened. THIS is the stock we think could rocket next...
One little-known Australian IPO has doubled in value since January, and renowned Australian Moonshot stock picker Anirban Mahanti sees a potential millionaire-maker in waiting...
Because 'Doc' Mahanti believes this fast-growing company has all the hallmarks of genuine Moonshot potential, forget 'buy now pay later', this stock could be the next hot stock on the ASX.
Returns as of 6th October 2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of VOLPARA FPO NZ. The Motley Fool Australia's parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited and Pro Medicus Ltd. The Motley Fool Australia has recommended VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- MyDeal (ASX:MYD) share price jumps 7% but tipped to go even higher – November 24, 2020 5:31pm
- Here’s why the Bravura Solutions (ASX:BVS) share price raced higher today – November 24, 2020 4:32pm
- 3 reasons the Redbubble (ASX:RBL) share price is in the buy zone – November 24, 2020 4:14pm